Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Date:1/29/2008

(a development stage company)

Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share amounts)

Period

from

February

4, 2002

inception

to

Three Months Twelve Months December

Ended December 31, Ended December 31, 31,

2006 2007 2006 2007 2007

Revenue:

Research revenue $- $1,375 $- $1,375 $1,375

Collaboration revenue - 409 - 409 409

Total revenue - 1,784 - 1,784 1,784

Operating Expenses:

Research and

development 14,186 9,670 33,630 31,074 89,878

General and

administrative 4,030 5,284 12,277 15,278 38,070

Impairment of

leasehold improvements - - - - 1,030

Depreciation and

amortization 291 313 952 1,237 2,794

In-process research

and development - - - - 418

Total operating

expenses 18,507 15,267 46,859 47,589 132,190

Loss from operations (18,507) (13,483) (46,859) (45,805) (130,406)

Other income (expenses):

Interest income 786 1,789 1,990 5,135 7,9
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
2. Amicus Therapeutics to Host R&D Day
3. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
4. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
5. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
6. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
7. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
9. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
10. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
11. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 1000 balances – 4 ... on customers’ weighing needs and expertly narrows down the ... balances, scales or even terminals. , First, select ... weight (or select readability instead) and define the accuracy ... selection criteria narrows down the list to models that ...
(Date:7/24/2014)... Draper University, a top program ... announce that for 6 weeks this summer, 39 ... on the Draper University campus in the heart ... focused on entrepreneurship, building real-world skills, and “learning ... its sixth cohort, continues to refresh its curriculum ...
(Date:7/24/2014)... July 24, 2014   Cypher Genomics, Inc., ... appointment of Adam Simpson as president ... rapid and comprehensive annotation and interpretation of individual ... "Cypher,s technology has the potential to ... enhancing diagnostic accuracy, optimizing therapeutic approaches and reducing ...
(Date:7/24/2014)... San Diego, CA (PRWEB) July 24, 2014 ... in the reporting of molecular diagnostic test results. ... tracking capabilities necessary for the validation and reporting ... in oncology. Molecular diagnostics is a rapidly growing ... for infectious disease, genetic predisposition, cancer, and companion ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2
... , , , , ... Primer anneal. temp. , Sensitivity , Specifi- , ... Tolerance , of non- , specific RNA , ... of serum components , Carry-over , prevention ...
... amplification of up to 3 kb genomic , DNA targets Cat. No. 1 647 679 ... 647 687 4 x 250 units (1 unit/l) , Cat. No. 1 146 165 100 ... Cat. No. 1 418 432 4 x 250 units (5 units/l) , ... 1 435 094 20 x 250 units (5 units/l) , , , , ...
... , Explore New Horizons in Amplification Yield, , ... High Yield, Accuracy, and the Prevention , of Carry-Over Contamination ... Roche Applied Science, which pioneered the blending , ... Long Template PCR Systems, now introduces the Expand High FidelityPLUS PCR , ...
Cached Biology Technology:Reverse transcriptases suitable for one-step RT-PCRb 2Taq DNA Polymerase 2Taq DNA Polymerase 3Expand High FidelityPLUS PCR System 2Expand High FidelityPLUS PCR System 3
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... provide much higher yield than their homozygous parents. Plant ... and used this effect called heterosis for richer harvests. ... underlying this phenomenon. Researchers at the University of Bonn ... decoded one possible mechanism in corn roots. More genes ...
... are known to be prodigious jumpers on land. Now, researchers ... , a Cell Press publication, have found that the tiny ... water, too. Their secret is a series of spring-loaded, oar-like ... have solved the most difficult task of jumping from the ...
... Grumman Corporation (NYSE: NOC ) has successfully ... biometric information system (ABIS) for the Australian Department of ... period to enable testing and refinement of analytical techniques ... the requirements for a future biometrics information management solution. ...
Cached Biology News:Corn: Many active genes - high yield 2Corn: Many active genes - high yield 3Pygmy mole crickets don't just walk on water, they jump on it 2Northrop Grumman Delivers Australian Automated Biometric Information System Trial Proof of Concept 2
Tube-O-DIALYZER Floats, small....
Feline Rhinotracheitis Virus...
Ezrin/Radixin/Moesin Antibody...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Biology Products: